The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
 
Theresa Medina
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst)
 
Jason Chesney
Consulting or Advisory Role - Iovance Biotherapeutics; Iovance Biotherapeutics
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Harriet Kluger
Consulting or Advisory Role - Bristol-Myers Squibb; ChemoCentryx; Clinigen Group; Eisai; GI Reviewers; Gigagen; Invox; Iovance Biotherapeutics; Merck; Pliant; Seranova Bio; Signatera; Werewolf Pharma
Speakers' Bureau - Merck
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Eric Whitman
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Castle Biosciences; Merck Sharp & Dohme; Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Genentech/Roche (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); OncoC4 (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Replimune (Inst); Seagen (Inst); Takeda (Inst); Toray Industries (Inst)
Patents, Royalties, Other Intellectual Property - Lighted Polyhedral surgical retractor; Nerve monitoring dissection device
 
Mike Cusnir
Speakers' Bureau - Guardant Health; Sirtex Medical
 
Sajeve Thomas
Consulting or Advisory Role - Amgen; Bristol Myers Squibb Foundation; Foundation One Inc; Genentech; Ipsen; Merck; Pfizer
Speakers' Bureau - Amgen; Bristol Myers Squibb Foundation; Foundation One Inc; Genentech; Ipsen; Merck; Pfizer
Research Funding - Amgen; Bristol Myers Squibb Foundation; Foundation One Inc; Genentech; Ipsen; Merck; Pfizer
Travel, Accommodations, Expenses - Amgen; Bristol Myers Squibb Foundation; Foundation One Inc; Genentech; Ipsen; Merck; Pfizer
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis
 
Evidio Domingo-Musibay
Research Funding - Instil Bio
 
Giao Phan
No Relationships to Disclose
 
John Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Ankyra Therapeutics; AXIO Research; Boxer Capital; Bristol Myers Squibb; CytomX Therapeutics; DermTech; Engage Health Media; iOnctura; Iovance Biotherapeutics; IQVIA; Istari Oncology; Jazz Pharmaceuticals; Lumira Capital Investment Management; Lytix Biopharma; Magnolia Innovation; Merck; Mural Oncology; Natera; Novartis; OncoCyte; PATHAI; Pfizer; Piper Sandler; PyrOjas Corporation; Regeneron; Replimune; Scopus BioPharma; Takeda; Valar Labs; Zola Therapeutics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Lion Biotechnologies (Inst); Lytix Biopharma (Inst); Novartis (Inst); Takeda (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Ankyra Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Iovance Biotherapeutics; Regeneron
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Ipsen; Merck Serono; Novartis; Pfizer; Roche; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Jeffrey Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; OncoC4; Turnstone Bio
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Turnstone Bio; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Roche; Sellas Life Sciences; Turnstone Bio; Turnstone Bio; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Moderna Therapeutics; Novartis; Roche
 
Friedrich Finckenstein
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Jeffrey Chou
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Brian Gastman
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Giri Sulur
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Renee Wu
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Rana Fiaz
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Amod Sarnaik
Honoraria - Clinical Education Alliance; Gerson Lehrman Group; Guidepoint Inc; Iovance Biotherapeutics; Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); MJH Healthcare Holdings, LLC; Second City LLC; Society for Immunotherapy of Cancer
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Bluprint Oncology Concepts; Iovance Biotherapeutics